|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Feasibility of predicting AML response to induction chemotherapy
|
1R43CA221473-01
|
$299,999
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS, LLC
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
1R43CA217502-01A1
|
$300,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-05
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-02
|
$44,044
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-03
|
$44,524
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
1R01CA217092-01
|
$397,371
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
5R01CA191077-03
|
$312,244
|
KOLB, EDWARD
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
|
Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade
|
1R43CA228319-01
|
$299,794
|
CHEN, RIDONG
|
APT THERAPEUTICS, INC.
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
Genetic Analysis of Myeloproliferative Disease
|
3R01CA076167-14S1
|
$24,361
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-16
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
PTEN, Tregs and MDSCs in the tumor microenvironment
|
5R01CA211229-02
|
$347,700
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-03
|
$44,524
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-04
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-05
|
$319,474
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
1R01CA207086-01A1
|
$326,540
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
5R01CA207086-02
|
$370,641
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITF
|
5R01CA193321-04
|
$362,569
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-04
|
$462,191
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|